-
(
DirixLY
TakacsI
JerusalemG
, et al. Avelumab, an anti-PD-L1 antibody, in patients with locally advanced or metastatic breast cancer: a phase 1b JAVELIN Solid Tumor study. Breast Cancer Res Treat
2018; 167: 671–686.29063313)
DirixLY
TakacsI
JerusalemG
, et al. Avelumab, an anti-PD-L1 antibody, in patients with locally advanced or metastatic breast cancer: a phase 1b JAVELIN Solid Tumor study. Breast Cancer Res Treat
2018; 167: 671–686.29063313
DirixLY
TakacsI
JerusalemG
, et al. Avelumab, an anti-PD-L1 antibody, in patients with locally advanced or metastatic breast cancer: a phase 1b JAVELIN Solid Tumor study. Breast Cancer Res Treat
2018; 167: 671–686.29063313,
DirixLY
TakacsI
JerusalemG
, et al. Avelumab, an anti-PD-L1 antibody, in patients with locally advanced or metastatic breast cancer: a phase 1b JAVELIN Solid Tumor study. Breast Cancer Res Treat
2018; 167: 671–686.29063313
-
(
Hadash-BengadR
HajajE
KleinS
, et al. Immunotherapy potentiates the effect of chemotherapy in metastatic melanoma—a retrospective study. Front Oncol
2020; 10: 70.32117727)
Hadash-BengadR
HajajE
KleinS
, et al. Immunotherapy potentiates the effect of chemotherapy in metastatic melanoma—a retrospective study. Front Oncol
2020; 10: 70.32117727
Hadash-BengadR
HajajE
KleinS
, et al. Immunotherapy potentiates the effect of chemotherapy in metastatic melanoma—a retrospective study. Front Oncol
2020; 10: 70.32117727,
Hadash-BengadR
HajajE
KleinS
, et al. Immunotherapy potentiates the effect of chemotherapy in metastatic melanoma—a retrospective study. Front Oncol
2020; 10: 70.32117727
-
Song-Ee
Park,
Se
Lee,
J.
Ahn,
M.
Ahn,
Keunchil
Park,
Jong-Mu
Sun
(2018)
Increased Response Rates to Salvage Chemotherapy Administered after PD‐1/PD‐L1 Inhibitors in Patients with Non–Small Cell Lung Cancer
Journal of Thoracic Oncology, 13
-
(
SchmidP
SalgadoR
ParkYH
, et al. Pembrolizumab plus chemotherapy as neoadjuvant treatment of high-risk, early-stage triple-negative breast cancer: results from the phase 1b open-label, multicohort KEYNOTE-173 study. Ann Oncol
2020; 31: 569–581.32278621)
SchmidP
SalgadoR
ParkYH
, et al. Pembrolizumab plus chemotherapy as neoadjuvant treatment of high-risk, early-stage triple-negative breast cancer: results from the phase 1b open-label, multicohort KEYNOTE-173 study. Ann Oncol
2020; 31: 569–581.32278621
SchmidP
SalgadoR
ParkYH
, et al. Pembrolizumab plus chemotherapy as neoadjuvant treatment of high-risk, early-stage triple-negative breast cancer: results from the phase 1b open-label, multicohort KEYNOTE-173 study. Ann Oncol
2020; 31: 569–581.32278621,
SchmidP
SalgadoR
ParkYH
, et al. Pembrolizumab plus chemotherapy as neoadjuvant treatment of high-risk, early-stage triple-negative breast cancer: results from the phase 1b open-label, multicohort KEYNOTE-173 study. Ann Oncol
2020; 31: 569–581.32278621
-
(
CasaresN
PequignotMO
TesniereA
, et al. Caspase-dependent immunogenicity of doxorubicin-induced tumor cell death. J Exp Med
2005; 202: 1691–1701.16365148)
CasaresN
PequignotMO
TesniereA
, et al. Caspase-dependent immunogenicity of doxorubicin-induced tumor cell death. J Exp Med
2005; 202: 1691–1701.16365148
CasaresN
PequignotMO
TesniereA
, et al. Caspase-dependent immunogenicity of doxorubicin-induced tumor cell death. J Exp Med
2005; 202: 1691–1701.16365148,
CasaresN
PequignotMO
TesniereA
, et al. Caspase-dependent immunogenicity of doxorubicin-induced tumor cell death. J Exp Med
2005; 202: 1691–1701.16365148
-
S.
Inogés,
S.
Tejada,
A.
Cerio,
J.
Pérez-Larraya,
J.
Espinós,
M.
Idoate,
Pablo
Domínguez,
Reyes
Eulate,
J.
Aristu,
M.
Bendandi,
F.
Pastor,
M.
Alonso,
E.
Andreu,
Felipe
Cardoso,
R.
Valle
(2017)
A phase II trial of autologous dendritic cell vaccination and radiochemotherapy following fluorescence-guided surgery in newly diagnosed glioblastoma patients
Journal of Translational Medicine, 15
-
(
LoiblS
UntchM
BurchardiN
, et al. A randomised phase II study investigating durvalumab in addition to an anthracycline taxane-based neoadjuvant therapy in early triple-negative breast cancer: clinical results and biomarker analysis of GeparNuevo study. Ann Oncol
2019; 30: 1279–1288.31095287)
LoiblS
UntchM
BurchardiN
, et al. A randomised phase II study investigating durvalumab in addition to an anthracycline taxane-based neoadjuvant therapy in early triple-negative breast cancer: clinical results and biomarker analysis of GeparNuevo study. Ann Oncol
2019; 30: 1279–1288.31095287
LoiblS
UntchM
BurchardiN
, et al. A randomised phase II study investigating durvalumab in addition to an anthracycline taxane-based neoadjuvant therapy in early triple-negative breast cancer: clinical results and biomarker analysis of GeparNuevo study. Ann Oncol
2019; 30: 1279–1288.31095287,
LoiblS
UntchM
BurchardiN
, et al. A randomised phase II study investigating durvalumab in addition to an anthracycline taxane-based neoadjuvant therapy in early triple-negative breast cancer: clinical results and biomarker analysis of GeparNuevo study. Ann Oncol
2019; 30: 1279–1288.31095287
-
H.
Rugo,
J.
Delord,
S.
Im,
P.
Ott,
S.
Piha-Paul,
Philippe
Bédard,
J.
Sachdev,
C.
Tourneau,
E.
Brummelen,
A.
Varga,
R.
Salgado,
S.
Loi,
S.
Saraf,
Dina
Pietrangelo,
V.
Karantza,
A.
Tan
(2018)
Safety and Antitumor Activity of Pembrolizumab in Patients with Estrogen Receptor–Positive/Human Epidermal Growth Factor Receptor 2–Negative Advanced Breast Cancer
Clinical Cancer Research, 24
-
(
SzekelyB
BossuytV
LiX
, et al. Immunological differences between primary and metastatic breast cancer. Ann Oncol
2018; 29: 2232–2239.30203045)
SzekelyB
BossuytV
LiX
, et al. Immunological differences between primary and metastatic breast cancer. Ann Oncol
2018; 29: 2232–2239.30203045
SzekelyB
BossuytV
LiX
, et al. Immunological differences between primary and metastatic breast cancer. Ann Oncol
2018; 29: 2232–2239.30203045,
SzekelyB
BossuytV
LiX
, et al. Immunological differences between primary and metastatic breast cancer. Ann Oncol
2018; 29: 2232–2239.30203045
-
J.
Cortés,
D.
Cescon,
H.
Rugo,
Z.
Nowecki,
S.
Im,
M.
Yusof,
C.
Gallardo,
O.
Lipatov,
C.
Barrios,
E.
Holgado,
H.
Iwata,
N.
Masuda,
M.
Otero,
E.
Gokmen,
S.
Loi,
Zifang
Guo,
Jingyi
Zhao,
G.
Aktan,
V.
Karantza,
P.
Schmid,
F.
Luis,
Gomez-Abuin
Gonzalo,
Kaen
Diego,
Kowalwszyn
Ruben,
Molina
Matias,
Varela
Mirta,
B.
Sally,
Begbie
Stephen,
Clingan
Philip,
Loi
Sherene,
S.
Dhanusha,
Gombos
Andrea,
Taylor
Donatienne,
Barrios
Carlos,
Brust
Leandro,
C.
Fabiano,
de
Ruffo,
Hegg
Roberto,
L.
Carvalho,
Lissa
Toniazzi,
Rocha
Odebrecht,
Scalabrini
Orlando,
S.
Felipe,
Cescon
David,
C.
Danielle,
Ferrario
Cristiano,
Song
Xinni,
Yu
Joanne,
Acevedo
Alejandro,
G.
Carlos,
Salas
Claudio,
Sanchez
Cesar,
Yanez
Eduardo,
Gomez
Alvaro,
S.
Jesus,
Holeckova
Petra,
Král
Zdeněk,
Melichar
Bohuslav,
Petrakova
Katarina,
Prausová
Jana,
Glavicic
Vesna,
Jakobsen
Erik,
Jensen
Jeanette,
Linnet
Soren,
Lőrincz
Tamás,
Bonnefoi
Herve,
D.
Isabelle,
Goncalves
Anthony,
Hardy-Bessard
Anne-Claire,
Teixeira
Luis,
Blohmer
Jens-Uwe,
Fasching
Peter,
Forstmeyer
Dirk,
H.
Nadia,
Huober
Jens,
Kaczerowsky
Anna,
Kurbacher
Christian,
L.
Sibylle,
Lueftner
Diana,
P-S
Tjoung-Won,
Schumann
Von,
Wimberger
Pauline,
C.
Louis,
K.
Ava,
N.
Roger,
Arkosy
Peter,
Csőszi
Tibor,
K.
Zsuzsanna,
Landherr
László,
Mahr
Karoly,
Rubovszky
Gábor,
C.
John,
Kelly
Catherine,
O.
Seamus,
Cinieri
Saverio,
DAlessio
Antonietta,
Ricevuto
Enrico,
Aruga
Tomoyuki,
Fujii
Takaaki,
Inoue
Kenichi,
Ishikawa
Takashi,
I.
Yoshinori,
Iwasaki
Tsutomu,
I.
Hiroji,
Kosaka
Yoshimasa,
Matsumoto
Koji,
Miyoshi
Yasuo,
Mukai
Hirofumi,
Nakamura
Seigo,
Niikura
Naoki,
Ohta
Shoichiro,
Osaki
Akihiko,
Sagara
Yasuaki,
Suzuki
Eiji,
Takahashi
Masato,
Tanabe
Yuko,
T.
Kenji,
Tsugawa
Koichiro,
Watanabe
Junichiro,
Yamamoto
Naohito,
Yamamoto
Yutaka,
Yamauchi
Teruo,
Bustam
Anita,
Md
Mastura,
Gomez
Angel,
Juarez
Alejandro,
Martinez
Jorge,
Morales-Vasquez
Flavia,
Reyes
Jessica,
Beelen
Karin,
Tjan-Heijnen
Vivianne,
P.
David,
Chmielowska
Ewa,
Nowakowska-Zajdel
Ewa,
Nowecki
Zbigniew,
Radecka
Barbara,
Streb
Joanna,
Szczylik
Cezary,
Tarnawski
Rafal,
Z.
Bogdan,
Arkhipov
Alexander,
Fadeeva
Natalia,
Lipatov
Oleg,
Meshcheryakov
Andrey,
Moiseyenko
Vladimir,
Mukhametshina
Guzel,
Ahn,
Hee,
Im,
Seock-Ah,
L.
Seok,
Park
Hwa,
park
hee,
Bermejo
Begona,
Cortés
Javier,
Cruz
Josefina,
de
Luis,
Garcia
Jose,
Gion
Maria,
H.
Esther,
Zamora
Esther,
Liu
Chien-Ting,
Liu
Mei-Ching,
Huang
Chiun-Sheng,
Tsao
Chao-Jung,
T.
Ling-Ming,
Arslan
Cagatay,
B.
Gul,
C.
Irfan,
Gokmen
Erhan,
Gunduz
Seyda,
Molinas
Nil,
Ozguroglu
Mustafa,
Ozyilkan
Ozgur,
Y.
Sinan,
Chan
Steve,
Graham
Janine,
MacPherson
Iain,
Schmid
Peter,
Turner
Nicholas,
T.
Mark,
Twelves
Christopher,
Wheatley
Duncan,
Adamchuk
Hryhoriy,
Berzoy
Oleksandr,
Bondarenko
Igor,
Kolesnik
Oleksii,
Kolesnik
Olena,
Komisarenko
Hanna,
Kryzhanivska
Anna,
Leshchenko
Iurii,
Nasonova
Alla,
Otchenash
Natalya,
Ponomarova
Olga,
Rusyn
Andrii,
Shevnya
Sergii,
Shparyk
Yaroslav,
Trukhin
Dmytro,
Ursol
Grygorii,
Vynnychenko
Ihor,
Blau
Sibel,
C.
Madhu,
C.
Michael,
C.
Patrick,
Cole
Scott,
D.
Jennifer,
G.
Keerthi,
H.
Jeffrey,
Hoskins
Kent,
I.
William,
Loutfi
Randa,
Lu
Janice,
M.
Raúl,
M.
Susan,
Nanda
Rita,
Oliff
Ira,
Omene
Coral,
P.
Timothy,
Panwalkar
Amit,
P.
Brian,
Rugo
Hope,
Rybalova
Irina,
Schleider
Michael,
Siegel
Robert,
Simon
Michael,
Stampleman
Laura,
Sumrall
Bradley,
Tsai
Michaela,
Valdes-Albini
Frances
(2020)
Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (KEYNOTE-355): a randomised, placebo-controlled, double-blind, phase 3 clinical trial
The Lancet, 396
-
(
KumariN
DwarakanathBS
DasA
, et al. Role of interleukin-6 in cancer progression and therapeutic resistance. Tumour Biol
2016; 37: 11553–11572.27260630)
KumariN
DwarakanathBS
DasA
, et al. Role of interleukin-6 in cancer progression and therapeutic resistance. Tumour Biol
2016; 37: 11553–11572.27260630
KumariN
DwarakanathBS
DasA
, et al. Role of interleukin-6 in cancer progression and therapeutic resistance. Tumour Biol
2016; 37: 11553–11572.27260630,
KumariN
DwarakanathBS
DasA
, et al. Role of interleukin-6 in cancer progression and therapeutic resistance. Tumour Biol
2016; 37: 11553–11572.27260630
-
Daniel
Chen,
I.
Mellman
(2017)
Elements of cancer immunity and the cancer–immune set point
Nature, 541
-
N.
Masuda,
Soo-Jung
Lee,
S.
Ohtani,
Y.
Im,
Eun-Sook
Lee,
I.
Yokota,
K.
Kuroi,
S.
Im,
Byeong-Woo
Park,
Sung-Bae
Kim,
Y.
Yanagita,
S.
Ohno,
S.
Takao,
K.
Aogi,
H.
Iwata,
Joon
Jeong,
Aeree
Kim,
K.
Park,
H.
Sasano,
Y.
Ohashi,
M.
Toi
(2017)
Adjuvant Capecitabine for Breast Cancer after Preoperative Chemotherapy
The New England Journal of Medicine, 376
-
S.
Loi,
N.
Sirtaine,
F.
Piette,
R.
Salgado,
G.
Viale,
F.
Eenoo,
G.
Rouas,
P.
Francis,
J.
Crown,
E.
Hitre,
E.
Azambuja,
E.
Quinaux,
A.
Leo,
S.
Michiels,
M.
Piccart,
C.
Sotiriou
(2013)
Prognostic and predictive value of tumor-infiltrating lymphocytes in a phase III randomized adjuvant breast cancer trial in node-positive breast cancer comparing the addition of docetaxel to doxorubicin with doxorubicin-based chemotherapy: BIG 02-98.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 31 7
-
N.
Casares,
M.
Péquignot,
A.
Tesnière,
F.
Ghiringhelli,
S.
Roux,
N.
Chaput,
E.
Schmitt,
Ahmed
Hamai,
S.
Hervás-Stubbs,
M.
Obeid,
F.
Coutant,
D.
Métivier,
E.
Pichard,
P.
Aucouturier,
G.
Pierron,
C.
Garrido,
L.
Zitvogel,
G.
Kroemer
(2005)
Caspase-dependent immunogenicity of doxorubicin-induced tumor cell death
The Journal of Experimental Medicine, 202
-
(
RugoHS
DelordJP
ImSA
, et al. Safety and antitumor activity of pembrolizumab in patients with estrogen receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer. Clin Cancer Res
2018; 24: 2804–2811.29559561)
RugoHS
DelordJP
ImSA
, et al. Safety and antitumor activity of pembrolizumab in patients with estrogen receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer. Clin Cancer Res
2018; 24: 2804–2811.29559561
RugoHS
DelordJP
ImSA
, et al. Safety and antitumor activity of pembrolizumab in patients with estrogen receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer. Clin Cancer Res
2018; 24: 2804–2811.29559561,
RugoHS
DelordJP
ImSA
, et al. Safety and antitumor activity of pembrolizumab in patients with estrogen receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer. Clin Cancer Res
2018; 24: 2804–2811.29559561
-
L.
Emens,
C.
Cruz,
J.
Eder,
F.
Braiteh,
C.
Chung,
S.
Tolaney,
I.
Kuter,
R.
Nanda,
P.
Cassier,
J.
Delord,
M.
Gordon,
E.
Elgabry,
Ching-Wei
Chang,
Indrani
Sarkar,
W.
Grossman,
C.
O'Hear,
M.
Fassò,
L.
Molinero,
P.
Schmid
(2019)
Long-term Clinical Outcomes and Biomarker Analyses of Atezolizumab Therapy for Patients With Metastatic Triple-Negative Breast Cancer: A Phase 1 Study
JAMA Oncology, 5
-
L.
Bracci,
G.
Schiavoni,
A.
Sistigu,
F.
Belardelli
(2013)
Immune-based mechanisms of cytotoxic chemotherapy: implications for the design of novel and rationale-based combined treatments against cancer
Cell Death and Differentiation, 21
-
(
NandaR
LiuMC
YauC
, et al. Effect of pembrolizumab plus neoadjuvant chemotherapy on pathologic complete response in women with early-stage breast cancer: an analysis of the ongoing phase 2 adaptively randomized I-SPY2 trial. JAMA Oncol
2020; 6: 676–684.32053137)
NandaR
LiuMC
YauC
, et al. Effect of pembrolizumab plus neoadjuvant chemotherapy on pathologic complete response in women with early-stage breast cancer: an analysis of the ongoing phase 2 adaptively randomized I-SPY2 trial. JAMA Oncol
2020; 6: 676–684.32053137
NandaR
LiuMC
YauC
, et al. Effect of pembrolizumab plus neoadjuvant chemotherapy on pathologic complete response in women with early-stage breast cancer: an analysis of the ongoing phase 2 adaptively randomized I-SPY2 trial. JAMA Oncol
2020; 6: 676–684.32053137,
NandaR
LiuMC
YauC
, et al. Effect of pembrolizumab plus neoadjuvant chemotherapy on pathologic complete response in women with early-stage breast cancer: an analysis of the ongoing phase 2 adaptively randomized I-SPY2 trial. JAMA Oncol
2020; 6: 676–684.32053137
-
P.
Cortazar,
Lijun
Zhang,
M.
Untch,
K.
Mehta,
J.
Costantino,
N.
Wolmark,
H.
Bonnefoi,
D.
Cameron,
L.
Gianni,
P.
Valagussa,
S.
Swain,
Tatiana
Prowell,
S.
Loibl,
L.
Wickerham,
J.
Bogaerts,
J.
Baselga,
C.
Perou,
G.
Blumenthal,
J.
Blohmer,
E.
Mamounas,
J.
Bergh,
V.
Semiglazov,
R.
Justice,
H.
Eidtmann,
S.
Paik,
M.
Piccart,
R.
Sridhara,
P.
Fasching,
L.
Slaets,
Shenghui
Tang,
B.
Gerber,
C.
Geyer,
R.
Pazdur,
N.
Ditsch,
P.
Rastogi,
W.
Eiermann,
G.
Minckwitz
(2014)
Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis
The Lancet, 384
-
(
MasudaN
LeeSJ
OhtaniS
, et al. Adjuvant capecitabine for breast cancer after preoperative chemotherapy. N Engl J Med
2017; 376: 2147–2159.28564564)
MasudaN
LeeSJ
OhtaniS
, et al. Adjuvant capecitabine for breast cancer after preoperative chemotherapy. N Engl J Med
2017; 376: 2147–2159.28564564
MasudaN
LeeSJ
OhtaniS
, et al. Adjuvant capecitabine for breast cancer after preoperative chemotherapy. N Engl J Med
2017; 376: 2147–2159.28564564,
MasudaN
LeeSJ
OhtaniS
, et al. Adjuvant capecitabine for breast cancer after preoperative chemotherapy. N Engl J Med
2017; 376: 2147–2159.28564564
-
E.
Mittendorf,
Hong
Zhang,
C.
Barrios,
S.
Saji,
K.
Jung,
R.
Hegg,
A.
Koehler,
J.
Sohn,
H.
Iwata,
M.
Telli,
C.
Ferrario,
K.
Punie,
F.
Penault-Llorca,
Shilpen
Patel,
A.
Duc,
M.
Liste-Hermoso,
V.
Maiya,
L.
Molinero,
S.
Chui,
N.
Harbeck
(2020)
Neoadjuvant atezolizumab in combination with sequential nab-paclitaxel and anthracycline-based chemotherapy versus placebo and chemotherapy in patients with early-stage triple-negative breast cancer (IMpassion031): a randomised, double-blind, phase 3 trial
The Lancet, 396
-
(
YamanakaR
HommaJ
YajimaN
, et al. Clinical evaluation of dendritic cell vaccination for patients with recurrent glioma: results of a clinical phase I/II trial. Clin Cancer Res
2005; 11: 4160–4167.15930352)
YamanakaR
HommaJ
YajimaN
, et al. Clinical evaluation of dendritic cell vaccination for patients with recurrent glioma: results of a clinical phase I/II trial. Clin Cancer Res
2005; 11: 4160–4167.15930352
YamanakaR
HommaJ
YajimaN
, et al. Clinical evaluation of dendritic cell vaccination for patients with recurrent glioma: results of a clinical phase I/II trial. Clin Cancer Res
2005; 11: 4160–4167.15930352,
YamanakaR
HommaJ
YajimaN
, et al. Clinical evaluation of dendritic cell vaccination for patients with recurrent glioma: results of a clinical phase I/II trial. Clin Cancer Res
2005; 11: 4160–4167.15930352
-
Christine
Dethlefsen,
Grith
Højfeldt,
P.
Hojman
(2013)
The role of intratumoral and systemic IL-6 in breast cancer
Breast Cancer Research and Treatment, 138
-
(
SolansBP
López-Díaz de CerioA
ElizaldeA
, et al. Assessing the impact of the addition of dendritic cell vaccination to neoadjuvant chemotherapy in breast cancer patients: a model-based characterization approach. Br J Clin Pharmacol
2019; 85: 1670–1683.30933365)
SolansBP
López-Díaz de CerioA
ElizaldeA
, et al. Assessing the impact of the addition of dendritic cell vaccination to neoadjuvant chemotherapy in breast cancer patients: a model-based characterization approach. Br J Clin Pharmacol
2019; 85: 1670–1683.30933365
SolansBP
López-Díaz de CerioA
ElizaldeA
, et al. Assessing the impact of the addition of dendritic cell vaccination to neoadjuvant chemotherapy in breast cancer patients: a model-based characterization approach. Br J Clin Pharmacol
2019; 85: 1670–1683.30933365,
SolansBP
López-Díaz de CerioA
ElizaldeA
, et al. Assessing the impact of the addition of dendritic cell vaccination to neoadjuvant chemotherapy in breast cancer patients: a model-based characterization approach. Br J Clin Pharmacol
2019; 85: 1670–1683.30933365
-
(
YuJS
LiuG
YingH
, et al. Vaccination with tumor lysate-pulsed dendritic cells elicits antigen-specific, cytotoxic T-cells in patients with malignant glioma. Cancer Res
2004; 64: 4973–4979.15256471)
YuJS
LiuG
YingH
, et al. Vaccination with tumor lysate-pulsed dendritic cells elicits antigen-specific, cytotoxic T-cells in patients with malignant glioma. Cancer Res
2004; 64: 4973–4979.15256471
YuJS
LiuG
YingH
, et al. Vaccination with tumor lysate-pulsed dendritic cells elicits antigen-specific, cytotoxic T-cells in patients with malignant glioma. Cancer Res
2004; 64: 4973–4979.15256471,
YuJS
LiuG
YingH
, et al. Vaccination with tumor lysate-pulsed dendritic cells elicits antigen-specific, cytotoxic T-cells in patients with malignant glioma. Cancer Res
2004; 64: 4973–4979.15256471
-
E.
Mittendorf,
A.
Philips,
F.
Meric-Bernstam,
N.
Qiao,
Yun
Wu,
S.
Harrington,
X.
Su,
Ying
Wang,
A.
González-Angulo,
A.
Akcakanat,
A.
Chawla,
M.
Curran,
P.
Hwu,
P.
Sharma,
J.
Litton,
J.
Molldrem,
G.
Alatrash
(2014)
PD-L1 Expression in Triple-Negative Breast Cancer
Cancer Immunology Research, 2
-
(
De VleeschouwerS
FieuwsS
RutkowskiS
, et al. Postoperative adjuvant dendritic cell-based immunotherapy in patients with relapsed glioblastoma multiforme. Clin Cancer Res
2008; 14: 3098–3104.18483377)
De VleeschouwerS
FieuwsS
RutkowskiS
, et al. Postoperative adjuvant dendritic cell-based immunotherapy in patients with relapsed glioblastoma multiforme. Clin Cancer Res
2008; 14: 3098–3104.18483377
De VleeschouwerS
FieuwsS
RutkowskiS
, et al. Postoperative adjuvant dendritic cell-based immunotherapy in patients with relapsed glioblastoma multiforme. Clin Cancer Res
2008; 14: 3098–3104.18483377,
De VleeschouwerS
FieuwsS
RutkowskiS
, et al. Postoperative adjuvant dendritic cell-based immunotherapy in patients with relapsed glioblastoma multiforme. Clin Cancer Res
2008; 14: 3098–3104.18483377
-
(
TumehPC
HarviewCL
YearleyJH
, et al. PD-1 blockade induces responses by inhibiting adaptive immune resistance. Nature
2014; 515: 568–571.25428505)
TumehPC
HarviewCL
YearleyJH
, et al. PD-1 blockade induces responses by inhibiting adaptive immune resistance. Nature
2014; 515: 568–571.25428505
TumehPC
HarviewCL
YearleyJH
, et al. PD-1 blockade induces responses by inhibiting adaptive immune resistance. Nature
2014; 515: 568–571.25428505,
TumehPC
HarviewCL
YearleyJH
, et al. PD-1 blockade induces responses by inhibiting adaptive immune resistance. Nature
2014; 515: 568–571.25428505
-
C.
Denkert,
G.
Minckwitz,
S.
Darb-Esfahani,
B.
Lederer,
B.
Heppner,
K.
Weber,
J.
Budczies,
J.
Huober,
F.
Klauschen,
J.
Furlanetto,
W.
Schmitt,
J.
Blohmer,
T.
Karn,
B.
Pfitzner,
S.
Kümmel,
K.
Engels,
A.
Schneeweiss,
A.
Hartmann,
A.
Noske,
P.
Fasching,
C.
Jackisch,
M.
Mackelenbergh,
P.
Sinn,
C.
Schem,
C.
Hanusch,
M.
Untch,
S.
Loibl
(2018)
Tumour-infiltrating lymphocytes and prognosis in different subtypes of breast cancer: a pooled analysis of 3771 patients treated with neoadjuvant therapy.
The Lancet. Oncology, 19 1
-
Reut
Hadash-Bengad,
E.
Hajaj,
Shiri
Klein,
S.
Merims,
S.
Frank,
G.
Eisenberg,
A.
Yakobson,
M.
Orevi,
N.
Caplan,
T.
Peretz,
M.
Lotem,
J.
Cohen
(2020)
Immunotherapy Potentiates the Effect of Chemotherapy in Metastatic Melanoma—A Retrospective Study
Frontiers in Oncology, 10
-
Nicole
Joller,
V.
Kuchroo
(2017)
Tim-3, Lag-3, and TIGIT.
Current topics in microbiology and immunology, 410
-
(
FieldsRC
ShimizuK
MuleJJ
. Murine dendritic cells pulsed with whole tumor lysates mediate potent antitumor immune responses in vitro and in vivo. Proc Natl Acad Sci USA
1998; 95: 9482–9487.9689106)
FieldsRC
ShimizuK
MuleJJ
. Murine dendritic cells pulsed with whole tumor lysates mediate potent antitumor immune responses in vitro and in vivo. Proc Natl Acad Sci USA
1998; 95: 9482–9487.9689106
FieldsRC
ShimizuK
MuleJJ
. Murine dendritic cells pulsed with whole tumor lysates mediate potent antitumor immune responses in vitro and in vivo. Proc Natl Acad Sci USA
1998; 95: 9482–9487.9689106,
FieldsRC
ShimizuK
MuleJJ
. Murine dendritic cells pulsed with whole tumor lysates mediate potent antitumor immune responses in vitro and in vivo. Proc Natl Acad Sci USA
1998; 95: 9482–9487.9689106
-
(
JollerN
KuchrooVK
. Tim-3, Lag-3, and TIGIT. Curr Top Microbiol Immunol
2017; 410: 127–156.28900677)
JollerN
KuchrooVK
. Tim-3, Lag-3, and TIGIT. Curr Top Microbiol Immunol
2017; 410: 127–156.28900677
JollerN
KuchrooVK
. Tim-3, Lag-3, and TIGIT. Curr Top Microbiol Immunol
2017; 410: 127–156.28900677,
JollerN
KuchrooVK
. Tim-3, Lag-3, and TIGIT. Curr Top Microbiol Immunol
2017; 410: 127–156.28900677
-
Ryan
Fields,
K.
Shimizu,
J.
Mulé
(1998)
Murine dendritic cells pulsed with whole tumor lysates mediate potent antitumor immune responses in vitro and in vivo.
Proceedings of the National Academy of Sciences of the United States of America, 95 16
-
(
SiegelRL
MillerKD
JemalA
. Cancer statistics, 2020. CA Cancer J Clin
2020; 70: 7–30.31912902)
SiegelRL
MillerKD
JemalA
. Cancer statistics, 2020. CA Cancer J Clin
2020; 70: 7–30.31912902
SiegelRL
MillerKD
JemalA
. Cancer statistics, 2020. CA Cancer J Clin
2020; 70: 7–30.31912902,
SiegelRL
MillerKD
JemalA
. Cancer statistics, 2020. CA Cancer J Clin
2020; 70: 7–30.31912902
-
L.
Gianni,
Chiun-Sheng
Huang,
D.
Egle,
B.
Bermejo,
C.
Zamagni,
M.
Thill,
A.
Antón,
S.
Zambelli,
G.
Bianchini,
S.
Russo,
E.
Ciruelos,
R.
Greil,
V.
Semiglazov,
M.
Colleoni,
C.
Kelly,
G.
Mariani,
L.
Mastro,
I.
Maffeis,
P.
Valagussa,
G.
Viale
(2020)
Abstract GS3-04: Pathologic complete response (pCR) to neoadjuvant treatment with or without atezolizumab in triple negative, early high-risk and locally advanced breast cancer. NeoTRIPaPDL1 Michelangelo randomized study
Cancer Research, 80
-
(
WheelerCJ
BlackKL
LiuG
, et al. Vaccination elicits correlated immune and clinical responses in glioblastoma multiforme patients. Cancer Res
2008; 68: 5955–5964.18632651)
WheelerCJ
BlackKL
LiuG
, et al. Vaccination elicits correlated immune and clinical responses in glioblastoma multiforme patients. Cancer Res
2008; 68: 5955–5964.18632651
WheelerCJ
BlackKL
LiuG
, et al. Vaccination elicits correlated immune and clinical responses in glioblastoma multiforme patients. Cancer Res
2008; 68: 5955–5964.18632651,
WheelerCJ
BlackKL
LiuG
, et al. Vaccination elicits correlated immune and clinical responses in glioblastoma multiforme patients. Cancer Res
2008; 68: 5955–5964.18632651
-
P.
Schmid,
H.
Rugo,
S.
Adams,
A.
Schneeweiss,
C.
Barrios,
H.
Iwata,
V.
Diéras,
V.
Henschel,
L.
Molinero,
S.
Chui,
V.
Maiya,
A.
Husain,
E.
Winer,
S.
Loi,
L.
Emens
(2019)
Atezolizumab plus nab-paclitaxel as first-line treatment for unresectable, locally advanced or metastatic triple-negative breast cancer (IMpassion130): updated efficacy results from a randomised, double-blind, placebo-controlled, phase 3 trial.
The Lancet. Oncology
-
(
CortesJ
CesconDW
RugoHS
, et al. Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (KEYNOTE-355): a randomised, placebo-controlled, double-blind, phase 3 clinical trial. Lancet
2020; 396: 1817–1828.33278935)
CortesJ
CesconDW
RugoHS
, et al. Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (KEYNOTE-355): a randomised, placebo-controlled, double-blind, phase 3 clinical trial. Lancet
2020; 396: 1817–1828.33278935
CortesJ
CesconDW
RugoHS
, et al. Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (KEYNOTE-355): a randomised, placebo-controlled, double-blind, phase 3 clinical trial. Lancet
2020; 396: 1817–1828.33278935,
CortesJ
CesconDW
RugoHS
, et al. Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (KEYNOTE-355): a randomised, placebo-controlled, double-blind, phase 3 clinical trial. Lancet
2020; 396: 1817–1828.33278935
-
Stephen
Luen,
Balaji
Virassamy,
P.
Savas,
R.
Salgado,
S.
Loi
(2016)
The genomic landscape of breast cancer and its interaction with host immunity.
Breast, 29
-
P.
Schmid,
J.
Cortés,
L.
Pusztai,
H.
McArthur,
S.
Kümmel,
J.
Bergh,
C.
Denkert,
Yeon-Hee
Park,
R.
Hui,
N.
Harbeck,
M.
Takahashi,
T.
Foukakis,
P.
Fasching,
F.
Cardoso,
M.
Untch,
L.
Jia,
V.
Karantza,
J.
Zhao,
G.
Aktan,
R.
Dent,
J.
O’Shaughnessy
(2020)
Pembrolizumab for Early Triple-Negative Breast Cancer.
The New England journal of medicine, 382 9
-
Neeraj
Kumari,
B.
Dwarakanath,
Asmita
Das,
A.
Bhatt
(2016)
Role of interleukin-6 in cancer progression and therapeutic resistance
Tumor Biology, 37
-
C.
Fadul,
J.
Fisher,
T.
Hampton,
E.
Lallana,
Zhongze
Li,
J.
Gui,
Z.
Szczepiorkowski,
T.
Tosteson,
C.
Rhodes,
H.
Wishart,
L.
Lewis,
M.
Ernstoff
(2011)
Immune Response in Patients With Newly Diagnosed Glioblastoma Multiforme Treated With Intranodal Autologous Tumor Lysate-dendritic Cell Vaccination After Radiation Chemotherapy
Journal of Immunotherapy, 34
-
C.
Wheeler,
K.
Black,
Gentao
Liu,
M.
Mazer,
Xiao-xue
Zhang,
S.
Pepkowitz,
D.
Goldfinger,
Hiushan
Ng,
Dwain
Irvin,
John
Yu
(2008)
Vaccination elicits correlated immune and clinical responses in glioblastoma multiforme patients.
Cancer research, 68 14
-
S.
Vleeschouwer,
S.
Fieuws,
S.
Rutkowski,
F.
Calenbergh,
J.
Loon,
J.
Goffin,
R.
Sciot,
G.
Wilms,
P.
Demaerel,
M.
Warmuth-Metz,
N.
Soerensen,
J.
Wolff,
S.
Wagner,
E.
Kaempgen,
S.
Gool
(2008)
Postoperative Adjuvant Dendritic Cell–Based Immunotherapy in Patients with Relapsed Glioblastoma Multiforme
Clinical Cancer Research, 14
-
(
FadulCE
FisherJL
HamptonTH
, et al. Immune response in patients with newly diagnosed glioblastoma multiforme treated with intranodal autologous tumor lysate-dendritic cell vaccination after radiation chemotherapy. J Immunother
2011; 34: 382–389.21499132)
FadulCE
FisherJL
HamptonTH
, et al. Immune response in patients with newly diagnosed glioblastoma multiforme treated with intranodal autologous tumor lysate-dendritic cell vaccination after radiation chemotherapy. J Immunother
2011; 34: 382–389.21499132
FadulCE
FisherJL
HamptonTH
, et al. Immune response in patients with newly diagnosed glioblastoma multiforme treated with intranodal autologous tumor lysate-dendritic cell vaccination after radiation chemotherapy. J Immunother
2011; 34: 382–389.21499132,
FadulCE
FisherJL
HamptonTH
, et al. Immune response in patients with newly diagnosed glioblastoma multiforme treated with intranodal autologous tumor lysate-dendritic cell vaccination after radiation chemotherapy. J Immunother
2011; 34: 382–389.21499132
-
P.
Tumeh,
C.
Harview,
J.
Yearley,
I.
Shintaku,
E.
Taylor,
L.
Robert,
B.
Chmielowski,
M.
Spasić,
G.
Henry,
V.
Ciobanu,
Alisha
West,
M.
Carmona,
C.
Kivork,
E.
Seja,
Grace
Cherry,
Antonio
Gutierrez,
T.
Grogan,
C.
Mateus,
G.
Tomasic,
J.
Glaspy,
R.
Emerson,
H.
Robins,
R.
Pierce,
D.
Elashoff,
C.
Robert,
A.
Ribas
(2014)
PD-1 blockade induces responses by inhibiting adaptive immune resistance
Nature, 515
-
(
InogesS
TejadaS
de CerioAL
, et al. A phase II trial of autologous dendritic cell vaccination and radiochemotherapy following fluorescence-guided surgery in newly diagnosed glioblastoma patients. J Transl Med
2017; 15: 104.28499389)
InogesS
TejadaS
de CerioAL
, et al. A phase II trial of autologous dendritic cell vaccination and radiochemotherapy following fluorescence-guided surgery in newly diagnosed glioblastoma patients. J Transl Med
2017; 15: 104.28499389
InogesS
TejadaS
de CerioAL
, et al. A phase II trial of autologous dendritic cell vaccination and radiochemotherapy following fluorescence-guided surgery in newly diagnosed glioblastoma patients. J Transl Med
2017; 15: 104.28499389,
InogesS
TejadaS
de CerioAL
, et al. A phase II trial of autologous dendritic cell vaccination and radiochemotherapy following fluorescence-guided surgery in newly diagnosed glioblastoma patients. J Transl Med
2017; 15: 104.28499389
-
P.
Schmid,
R.
Salgado,
Yeon-Hee
Park,
E.
Muñoz-Couselo,
Sung-Bae
Kim,
J.
Sohn,
S.
Im,
T.
Foukakis,
S.
Kuemmel,
R.
Dent,
L.
Yin,
A.
Wang,
K.
Tryfonidis,
V.
Karantza,
J.
Cortés,
S.
Loi
(2020)
Pembrolizumab plus chemotherapy as neoadjuvant treatment of high-risk, early-stage triple-negative breast cancer: results from the phase 1b open-label, multicohort KEYNOTE-173 study.
Annals of oncology : official journal of the European Society for Medical Oncology
-
B.
Szekely,
V.
Bossuyt,
Xiaotong
Li,
V.
Wali,
G.
Patwardhan,
Courtney
Frederick,
Andrea
Silber,
Tristen
Park,
M.
Harigopal,
V.
Pelekanou,
Meiling
Zhang,
Qin
Yan,
D.
Rimm,
G.
Bianchini,
C.
Hatzis,
Lajos
Pusztai
(2018)
Immunological differences between primary and metastatic breast cancer
Annals of Oncology, 29
-
L.
Dirix,
I.
Takács,
G.
Jerusalem,
P.
Nikolinakos,
H.
Arkenau,
A.
Forero-Torres,
R.
Boccia,
M.
Lippman,
R.
Somer,
M.
Šmakal,
L.
Emens,
B.
Hrinczenko,
W.
Edenfield,
J.
Gurtler,
A.
Heydebreck,
H.
Grote,
K.
Chin,
E.
Hamilton
(2017)
Avelumab, an anti-PD-L1 antibody, in patients with locally advanced or metastatic breast cancer: a phase 1b JAVELIN Solid Tumor study
Breast Cancer Research and Treatment, 167
-
(
QiCJ
NingYL
HanYS
, et al. Autologous dendritic cell vaccine for estrogen receptor (ER)/progestin receptor (PR) double-negative breast cancer. Cancer Immunol Immunother
2012; 61: 1415–1424.22290073)
QiCJ
NingYL
HanYS
, et al. Autologous dendritic cell vaccine for estrogen receptor (ER)/progestin receptor (PR) double-negative breast cancer. Cancer Immunol Immunother
2012; 61: 1415–1424.22290073
QiCJ
NingYL
HanYS
, et al. Autologous dendritic cell vaccine for estrogen receptor (ER)/progestin receptor (PR) double-negative breast cancer. Cancer Immunol Immunother
2012; 61: 1415–1424.22290073,
QiCJ
NingYL
HanYS
, et al. Autologous dendritic cell vaccine for estrogen receptor (ER)/progestin receptor (PR) double-negative breast cancer. Cancer Immunol Immunother
2012; 61: 1415–1424.22290073
-
Chun-jian
Qi,
Yongling
Ning,
Ye-Shan
Han,
Hai-Yan
Min,
Heng
Ye,
Yu-lan
Zhu,
Ke-Qing
Qian
(2012)
Autologous dendritic cell vaccine for estrogen receptor (ER)/progestin receptor (PR) double-negative breast cancer
Cancer Immunology, Immunotherapy, 61
-
Administrative, technical, or material support (i.e. reporting or organizing data, constructing databases: BP Solans
-
K.
Baker,
A.
Houston,
E.
Brint
(2019)
IL-1 Family Members in Cancer; Two Sides to Every Story
Frontiers in Immunology, 10
-
(
ParkSE
LeeSH
AhnJS
, et al. Increased response rates to salvage chemotherapy administered after PD-1/PD-L1 inhibitors in patients with non-small cell lung cancer. J Thorac Oncol
2018; 13: 106–111.29101058)
ParkSE
LeeSH
AhnJS
, et al. Increased response rates to salvage chemotherapy administered after PD-1/PD-L1 inhibitors in patients with non-small cell lung cancer. J Thorac Oncol
2018; 13: 106–111.29101058
ParkSE
LeeSH
AhnJS
, et al. Increased response rates to salvage chemotherapy administered after PD-1/PD-L1 inhibitors in patients with non-small cell lung cancer. J Thorac Oncol
2018; 13: 106–111.29101058,
ParkSE
LeeSH
AhnJS
, et al. Increased response rates to salvage chemotherapy administered after PD-1/PD-L1 inhibitors in patients with non-small cell lung cancer. J Thorac Oncol
2018; 13: 106–111.29101058
-
(
ProwellTM
PazdurR
. Pathological complete response and accelerated drug approval in early breast cancer. N Engl J Med
2012; 366: 2438–2441.22646508)
ProwellTM
PazdurR
. Pathological complete response and accelerated drug approval in early breast cancer. N Engl J Med
2012; 366: 2438–2441.22646508
ProwellTM
PazdurR
. Pathological complete response and accelerated drug approval in early breast cancer. N Engl J Med
2012; 366: 2438–2441.22646508,
ProwellTM
PazdurR
. Pathological complete response and accelerated drug approval in early breast cancer. N Engl J Med
2012; 366: 2438–2441.22646508
-
R.
Nanda,
Minetta
Liu,
C.
Yau,
Rebecca
Shatsky,
L.
Pusztai,
A.
Wallace,
A.
Chien,
A.
Forero-Torres,
E.
Ellis,
Heather
Han,
A.
Clark,
K.
Albain,
J.
Boughey,
N.
Jaskowiak,
A.
Elias,
C.
Isaacs,
K.
Kemmer,
T.
Helsten,
M.
Majure,
E.
Stringer-Reasor,
C.
Parker,
Marie
Lee,
T.
Haddad,
Ronald
Cohen,
S.
Asare,
Amy
Wilson,
G.
Hirst,
R.
Singhrao,
K.
Steeg,
A.
Asare,
J.
Matthews,
S.
Berry,
A.
Sanil,
R.
Schwab,
W.
Symmans,
L.
Veer,
D.
Yee,
A.
DeMichele,
N.
Hylton,
M.
Melisko,
J.
Perlmutter,
H.
Rugo,
D.
Berry,
L.
Esserman
(2020)
Effect of Pembrolizumab Plus Neoadjuvant Chemotherapy on Pathologic Complete Response in Women With Early-Stage Breast Cancer: An Analysis of the Ongoing Phase 2 Adaptively Randomized I-SPY2 Trial.
JAMA oncology
-
Tatiana
Prowell,
R.
Pazdur
(2012)
Pathological complete response and accelerated drug approval in early breast cancer.
The New England journal of medicine, 366 26
-
(
ChenDS
MellmanI
. Elements of cancer immunity and the cancer-immune set point. Nature
2017; 541: 321–330.28102259)
ChenDS
MellmanI
. Elements of cancer immunity and the cancer-immune set point. Nature
2017; 541: 321–330.28102259
ChenDS
MellmanI
. Elements of cancer immunity and the cancer-immune set point. Nature
2017; 541: 321–330.28102259,
ChenDS
MellmanI
. Elements of cancer immunity and the cancer-immune set point. Nature
2017; 541: 321–330.28102259
-
(
BracciL
SchiavoniG
SistiguA
, et al. Immune-based mechanisms of cytotoxic chemotherapy: implications for the design of novel and rationale-based combined treatments against cancer. Cell Death Differ
2014; 21: 15–25.23787994)
BracciL
SchiavoniG
SistiguA
, et al. Immune-based mechanisms of cytotoxic chemotherapy: implications for the design of novel and rationale-based combined treatments against cancer. Cell Death Differ
2014; 21: 15–25.23787994
BracciL
SchiavoniG
SistiguA
, et al. Immune-based mechanisms of cytotoxic chemotherapy: implications for the design of novel and rationale-based combined treatments against cancer. Cell Death Differ
2014; 21: 15–25.23787994,
BracciL
SchiavoniG
SistiguA
, et al. Immune-based mechanisms of cytotoxic chemotherapy: implications for the design of novel and rationale-based combined treatments against cancer. Cell Death Differ
2014; 21: 15–25.23787994
-
K.
Hutchinson,
S.
Yost,
Ching-Wei
Chang,
Radia
Johnson,
Adrian
Carr,
P.
McAdam,
D.
Halligan,
Chun-Chieh
Chang,
D.
Schmolze,
Jackson
Liang,
Yuan
Yuan
(2019)
Comprehensive Profiling of Poor-Risk Paired Primary and Recurrent Triple-Negative Breast Cancers Reveals Immune Phenotype Shifts
Clinical Cancer Research, 26
-
(
GianniL
HuangC-S
EgleD
, et al. Abstract GS3-04: Pathologic complete response (pCR) to neoadjuvant treatment with or without atezolizumab in triple negative, early high-risk and locally advanced breast cancer. NeoTRIPaPDL1 Michelangelo randomized study. Cancer Res
2020; 80: GS3-04.)
GianniL
HuangC-S
EgleD
, et al. Abstract GS3-04: Pathologic complete response (pCR) to neoadjuvant treatment with or without atezolizumab in triple negative, early high-risk and locally advanced breast cancer. NeoTRIPaPDL1 Michelangelo randomized study. Cancer Res
2020; 80: GS3-04.
GianniL
HuangC-S
EgleD
, et al. Abstract GS3-04: Pathologic complete response (pCR) to neoadjuvant treatment with or without atezolizumab in triple negative, early high-risk and locally advanced breast cancer. NeoTRIPaPDL1 Michelangelo randomized study. Cancer Res
2020; 80: GS3-04.,
GianniL
HuangC-S
EgleD
, et al. Abstract GS3-04: Pathologic complete response (pCR) to neoadjuvant treatment with or without atezolizumab in triple negative, early high-risk and locally advanced breast cancer. NeoTRIPaPDL1 Michelangelo randomized study. Cancer Res
2020; 80: GS3-04.
-
L.
Emens,
G.
Middleton
(2015)
The Interplay of Immunotherapy and Chemotherapy: Harnessing Potential Synergies
Cancer Immunology Research, 3
-
(
SalehK
DasteA
MartinN
, et al. Response to salvage chemotherapy after progression on immune checkpoint inhibitors in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck. Eur J Cancer
2019; 121: 123–129.31574417)
SalehK
DasteA
MartinN
, et al. Response to salvage chemotherapy after progression on immune checkpoint inhibitors in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck. Eur J Cancer
2019; 121: 123–129.31574417
SalehK
DasteA
MartinN
, et al. Response to salvage chemotherapy after progression on immune checkpoint inhibitors in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck. Eur J Cancer
2019; 121: 123–129.31574417,
SalehK
DasteA
MartinN
, et al. Response to salvage chemotherapy after progression on immune checkpoint inhibitors in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck. Eur J Cancer
2019; 121: 123–129.31574417
-
(
DethlefsenC
HojfeldtG
HojmanP
. The role of intratumoral and systemic IL-6 in breast cancer. Breast Cancer Res Treat
2013; 138: 657–664.23532539)
DethlefsenC
HojfeldtG
HojmanP
. The role of intratumoral and systemic IL-6 in breast cancer. Breast Cancer Res Treat
2013; 138: 657–664.23532539
DethlefsenC
HojfeldtG
HojmanP
. The role of intratumoral and systemic IL-6 in breast cancer. Breast Cancer Res Treat
2013; 138: 657–664.23532539,
DethlefsenC
HojfeldtG
HojmanP
. The role of intratumoral and systemic IL-6 in breast cancer. Breast Cancer Res Treat
2013; 138: 657–664.23532539
-
R.
Yamanaka,
J.
Homma,
N.
Yajima,
Naoto
Tsuchiya,
Masakazu
Sano,
Tsutomu
Kobayashi,
S.
Yoshida,
T.
Abe,
M.
Narita,
Masuhiro
Takahashi,
R.
Tanaka
(2005)
Clinical evaluation of dendritic cell vaccination for patients with recurrent glioma: results of a clinical phase I/II trial.
Clinical cancer research : an official journal of the American Association for Cancer Research, 11 11
-
R.
Siegel,
K.
Miller,
A.
Jemal
(2020)
Cancer statistics, 2020
CA: A Cancer Journal for Clinicians, 70
-
(
LuenS
VirassamyB
SavasP
, et al. The genomic landscape of breast cancer and its interaction with host immunity. Breast
2016; 29: 241–250.27481651)
LuenS
VirassamyB
SavasP
, et al. The genomic landscape of breast cancer and its interaction with host immunity. Breast
2016; 29: 241–250.27481651
LuenS
VirassamyB
SavasP
, et al. The genomic landscape of breast cancer and its interaction with host immunity. Breast
2016; 29: 241–250.27481651,
LuenS
VirassamyB
SavasP
, et al. The genomic landscape of breast cancer and its interaction with host immunity. Breast
2016; 29: 241–250.27481651
-
(
Sobral-LeiteM
SalomonI
OpdamM
, et al. Cancer-immune interactions in ER-positive breast cancers: PI3K pathway alterations and tumor-infiltrating lymphocytes. Breast Cancer Res
2019; 21: 90.31391067)
Sobral-LeiteM
SalomonI
OpdamM
, et al. Cancer-immune interactions in ER-positive breast cancers: PI3K pathway alterations and tumor-infiltrating lymphocytes. Breast Cancer Res
2019; 21: 90.31391067
Sobral-LeiteM
SalomonI
OpdamM
, et al. Cancer-immune interactions in ER-positive breast cancers: PI3K pathway alterations and tumor-infiltrating lymphocytes. Breast Cancer Res
2019; 21: 90.31391067,
Sobral-LeiteM
SalomonI
OpdamM
, et al. Cancer-immune interactions in ER-positive breast cancers: PI3K pathway alterations and tumor-infiltrating lymphocytes. Breast Cancer Res
2019; 21: 90.31391067
-
(
EmensLA
CruzC
EderJP
, et al. Long-term clinical outcomes and biomarker analyses of atezolizumab therapy for patients with metastatic triple-negative breast cancer: a phase 1 study. JAMA Oncol
2019; 5: 74–82.30242306)
EmensLA
CruzC
EderJP
, et al. Long-term clinical outcomes and biomarker analyses of atezolizumab therapy for patients with metastatic triple-negative breast cancer: a phase 1 study. JAMA Oncol
2019; 5: 74–82.30242306
EmensLA
CruzC
EderJP
, et al. Long-term clinical outcomes and biomarker analyses of atezolizumab therapy for patients with metastatic triple-negative breast cancer: a phase 1 study. JAMA Oncol
2019; 5: 74–82.30242306,
EmensLA
CruzC
EderJP
, et al. Long-term clinical outcomes and biomarker analyses of atezolizumab therapy for patients with metastatic triple-negative breast cancer: a phase 1 study. JAMA Oncol
2019; 5: 74–82.30242306
-
(
HutchinsonKE
YostSE
ChangCW
, et al. Comprehensive profiling of poor-risk paired primary and recurrent triple-negative breast cancers reveals immune phenotype shifts. Clin Cancer Res
2020; 26: 657–668.31611282)
HutchinsonKE
YostSE
ChangCW
, et al. Comprehensive profiling of poor-risk paired primary and recurrent triple-negative breast cancers reveals immune phenotype shifts. Clin Cancer Res
2020; 26: 657–668.31611282
HutchinsonKE
YostSE
ChangCW
, et al. Comprehensive profiling of poor-risk paired primary and recurrent triple-negative breast cancers reveals immune phenotype shifts. Clin Cancer Res
2020; 26: 657–668.31611282,
HutchinsonKE
YostSE
ChangCW
, et al. Comprehensive profiling of poor-risk paired primary and recurrent triple-negative breast cancers reveals immune phenotype shifts. Clin Cancer Res
2020; 26: 657–668.31611282
-
K.
Saleh,
A.
Daste,
N.
Martin,
E.
Pons-Tostivint,
A.
Aupérin,
Ruth
Herrera-Gómez,
N.
Baste-Rotllan,
F.
Bidault,
J.
Guigay,
C.
Tourneau,
E.
Saâda-Bouzid,
C.
Even
(2019)
Response to salvage chemotherapy after progression on immune checkpoint inhibitors in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck.
European journal of cancer, 121
-
(
MittendorfEA
PhilipsAV
Meric-BernstamF
, et al. PD-L1 expression in triple-negative breast cancer. Cancer Immunol Res
2014; 2: 361–370.24764583)
MittendorfEA
PhilipsAV
Meric-BernstamF
, et al. PD-L1 expression in triple-negative breast cancer. Cancer Immunol Res
2014; 2: 361–370.24764583
MittendorfEA
PhilipsAV
Meric-BernstamF
, et al. PD-L1 expression in triple-negative breast cancer. Cancer Immunol Res
2014; 2: 361–370.24764583,
MittendorfEA
PhilipsAV
Meric-BernstamF
, et al. PD-L1 expression in triple-negative breast cancer. Cancer Immunol Res
2014; 2: 361–370.24764583
-
(
BakerKJ
HoustonA
BrintE
. IL-1 family members in cancer; two sides to every story. Front Immunol
2019; 10: 1197.)
BakerKJ
HoustonA
BrintE
. IL-1 family members in cancer; two sides to every story. Front Immunol
2019; 10: 1197.
BakerKJ
HoustonA
BrintE
. IL-1 family members in cancer; two sides to every story. Front Immunol
2019; 10: 1197.,
BakerKJ
HoustonA
BrintE
. IL-1 family members in cancer; two sides to every story. Front Immunol
2019; 10: 1197.
-
M.
Sobral-Leite,
Izhar
Salomon,
M.
Opdam,
D.
Kruger,
K.
Beelen,
V.
Noort,
R.
Vlierberghe,
E.
Blok,
D.
Giardiello,
J.
Sanders,
K.
Vijver,
H.
Horlings,
P.
Kuppen,
S.
Linn,
M.
Schmidt,
M.
Kok
(2019)
Cancer-immune interactions in ER-positive breast cancers: PI3K pathway alterations and tumor-infiltrating lymphocytes
Breast Cancer Research : BCR, 21
-
(
Martin-RomanoP
AmmariS
El-DakdouktiY
, et al. Chemotherapy beyond immune checkpoint inhibitors in patients with metastatic colorectal cancer. Eur J Cancer
2020; 137: 117–126.32755794)
Martin-RomanoP
AmmariS
El-DakdouktiY
, et al. Chemotherapy beyond immune checkpoint inhibitors in patients with metastatic colorectal cancer. Eur J Cancer
2020; 137: 117–126.32755794
Martin-RomanoP
AmmariS
El-DakdouktiY
, et al. Chemotherapy beyond immune checkpoint inhibitors in patients with metastatic colorectal cancer. Eur J Cancer
2020; 137: 117–126.32755794,
Martin-RomanoP
AmmariS
El-DakdouktiY
, et al. Chemotherapy beyond immune checkpoint inhibitors in patients with metastatic colorectal cancer. Eur J Cancer
2020; 137: 117–126.32755794
-
S.
Loibl,
M.
Untch,
N.
Burchardi,
J.
Huober,
B.
Sinn,
J.
Blohmer,
E.
Grischke,
J.
Furlanetto,
H.
Tesch,
C.
Hanusch,
K.
Engels,
M.
Rezai,
C.
Jackisch,
W.
Schmitt,
G.
Minckwitz,
Jörg
Thomalla,
S.
Kümmel,
B.
Rautenberg,
P.
Fasching,
K.
Weber,
K.
Rhiem,
C.
Denkert,
A.
Schneeweiss
(2019)
A randomised phase II study investigating durvalumab in addition to an anthracycline taxane-based neoadjuvant therapy in early triple negative breast cancer - clinical results and biomarker analysis of GeparNuevo study.
Annals of oncology : official journal of the European Society for Medical Oncology
-
Development of methodology: BP Solans
-
(
ParkJH
JangM
TarhanYE
, et al. Clonal expansion of antitumor T cells in breast cancer correlates with response to neoadjuvant chemotherapy. Int J Oncol
2016; 49: 471–478.27278091)
ParkJH
JangM
TarhanYE
, et al. Clonal expansion of antitumor T cells in breast cancer correlates with response to neoadjuvant chemotherapy. Int J Oncol
2016; 49: 471–478.27278091
ParkJH
JangM
TarhanYE
, et al. Clonal expansion of antitumor T cells in breast cancer correlates with response to neoadjuvant chemotherapy. Int J Oncol
2016; 49: 471–478.27278091,
ParkJH
JangM
TarhanYE
, et al. Clonal expansion of antitumor T cells in breast cancer correlates with response to neoadjuvant chemotherapy. Int J Oncol
2016; 49: 471–478.27278091
-
(
FinakG
BertosN
PepinF
, et al. Stromal gene expression predicts clinical outcome in breast cancer. Nat Med
2008; 14: 518–527.18438415)
FinakG
BertosN
PepinF
, et al. Stromal gene expression predicts clinical outcome in breast cancer. Nat Med
2008; 14: 518–527.18438415
FinakG
BertosN
PepinF
, et al. Stromal gene expression predicts clinical outcome in breast cancer. Nat Med
2008; 14: 518–527.18438415,
FinakG
BertosN
PepinF
, et al. Stromal gene expression predicts clinical outcome in breast cancer. Nat Med
2008; 14: 518–527.18438415
-
John
Yu,
Gentao
Liu,
H.
Ying,
W.
Yong,
K.
Black,
C.
Wheeler
(2004)
Vaccination with Tumor Lysate-Pulsed Dendritic Cells Elicits Antigen-Specific, Cytotoxic T-Cells in Patients with Malignant Glioma
Cancer Research, 64
-
(
LoiS
SirtaineN
PietteF
, et al. Prognostic and predictive value of tumor-infiltrating lymphocytes in a phase III randomized adjuvant breast cancer trial in node-positive breast cancer comparing the addition of docetaxel to doxorubicin with doxorubicin-based chemotherapy: BIG 02-98. J Clin Oncol
2013; 31: 860–867.23341518)
LoiS
SirtaineN
PietteF
, et al. Prognostic and predictive value of tumor-infiltrating lymphocytes in a phase III randomized adjuvant breast cancer trial in node-positive breast cancer comparing the addition of docetaxel to doxorubicin with doxorubicin-based chemotherapy: BIG 02-98. J Clin Oncol
2013; 31: 860–867.23341518
LoiS
SirtaineN
PietteF
, et al. Prognostic and predictive value of tumor-infiltrating lymphocytes in a phase III randomized adjuvant breast cancer trial in node-positive breast cancer comparing the addition of docetaxel to doxorubicin with doxorubicin-based chemotherapy: BIG 02-98. J Clin Oncol
2013; 31: 860–867.23341518,
LoiS
SirtaineN
PietteF
, et al. Prognostic and predictive value of tumor-infiltrating lymphocytes in a phase III randomized adjuvant breast cancer trial in node-positive breast cancer comparing the addition of docetaxel to doxorubicin with doxorubicin-based chemotherapy: BIG 02-98. J Clin Oncol
2013; 31: 860–867.23341518
-
P.
Martin-Romano,
S.
Ammari,
Yolla
El-Dakdoukti,
C.
Baldini,
A.
Varga,
P.
Vuagnat,
E.
Angevin,
R.
Bahleda,
A.
Gazzah,
S.
Champiat,
J.
Michot,
S.
Postel-Vinay,
A.
Marabelle,
J.
Soria,
V.
Boige,
D.
Malka,
M.
Ducreux,
C.
Massard,
A.
Hollebecque
(2020)
Chemotherapy beyond immune checkpoint inhibitors in patients with metastatic colorectal cancer.
European journal of cancer, 137
-
B.
Solans,
A.
Cerio,
A.
Elizalde,
L.
Pina,
S.
Inogés,
J.
Espinós,
E.
Salgado,
L.
Mejías,
I.
Trocóniz,
M.
Santisteban
(2019)
Assessing the impact of the addition of dendritic cell vaccination to neoadjuvant chemotherapy in breast cancer patients: A model‐based characterization approach
British Journal of Clinical Pharmacology, 85
-
Jae-Hyun
Park,
Miran
Jang,
Yunus
Tarhan,
T.
Katagiri,
M.
Sasa,
Y.
Miyoshi,
Krishna
Kalari,
V.
Suman,
R.
Weinshilboum,
Liewei
Wang,
J.
Boughey,
M.
Goetz,
Yusuke
Nakamura
(2016)
Clonal expansion of antitumor T cells in breast cancer correlates with response to neoadjuvant chemotherapy
International Journal of Oncology, 49
-
(
CortazarP
ZhangL
UntchM
, et al. Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis. Lancet
2014; 384: 164–172.24529560)
CortazarP
ZhangL
UntchM
, et al. Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis. Lancet
2014; 384: 164–172.24529560
CortazarP
ZhangL
UntchM
, et al. Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis. Lancet
2014; 384: 164–172.24529560,
CortazarP
ZhangL
UntchM
, et al. Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis. Lancet
2014; 384: 164–172.24529560
-
(
DenkertC
von MinckwitzG
Darb-EsfahaniS
, et al. Tumour-infiltrating lymphocytes and prognosis in different subtypes of breast cancer: a pooled analysis of 3771 patients treated with neoadjuvant therapy. Lancet Oncol
2018; 19: 40–50.29233559)
DenkertC
von MinckwitzG
Darb-EsfahaniS
, et al. Tumour-infiltrating lymphocytes and prognosis in different subtypes of breast cancer: a pooled analysis of 3771 patients treated with neoadjuvant therapy. Lancet Oncol
2018; 19: 40–50.29233559
DenkertC
von MinckwitzG
Darb-EsfahaniS
, et al. Tumour-infiltrating lymphocytes and prognosis in different subtypes of breast cancer: a pooled analysis of 3771 patients treated with neoadjuvant therapy. Lancet Oncol
2018; 19: 40–50.29233559,
DenkertC
von MinckwitzG
Darb-EsfahaniS
, et al. Tumour-infiltrating lymphocytes and prognosis in different subtypes of breast cancer: a pooled analysis of 3771 patients treated with neoadjuvant therapy. Lancet Oncol
2018; 19: 40–50.29233559
-
Greg
Finak,
N.
Bertos,
F.
Pépin,
S.
Sadekova,
Margarita
Souleimanova,
Hong
Zhao,
Haiying
Chen,
Gulbeyaz
Omeroglu,
S.
Meterissian,
A.
Omeroglu,
M.
Hallett,
Morag
Park
(2008)
Stromal gene expression predicts clinical outcome in breast cancer
Nature Medicine, 14